Acquiring an existing Medicare-certified hospice versus launching a de novo agency involves very different cost structures, timelines, and regulatory hurdles. Here is how to decide which path is right for your strategy.
The hospice and palliative care industry presents a compelling opportunity for healthcare investors and operators, but the path to market entry matters enormously. Acquiring an established, Medicare-certified hospice agency gives you an operating census, licensed staff, referral relationships, and a billing track record from day one. Building a de novo agency means navigating a 12–24 month certification and ramp-up process before meaningful revenue flows, with no guarantee of referral traction in a relationship-driven business. For most lower middle market buyers — regional platform operators, PE-backed roll-ups, and experienced healthcare entrepreneurs — acquisition is the faster, lower-risk path to scale. But de novo development can make sense in specific geographies or for operators with deep clinical networks and patience for a longer return horizon. This analysis gives you a rigorous, side-by-side framework to evaluate both options in the context of the hospice industry.
Find Hospice & Palliative Care Businesses to AcquireAcquiring an existing Medicare-certified hospice agency gives you immediate access to an operating business: an established average daily census (ADC), licensed and tenured clinical staff, a functioning referral network, and a reimbursement history with CMS. In a relationship-driven, compliance-intensive industry like hospice, these assets are extraordinarily difficult and time-consuming to replicate from scratch. For buyers targeting $1M–$5M revenue businesses with $300K–$1.5M EBITDA, a well-underwritten acquisition typically generates cash flow from the first month post-close.
PE-backed hospice platforms executing geographic roll-up strategies, regional home health operators seeking to add a hospice license and census, and experienced healthcare operators who want cash-flowing assets without a de novo ramp-up period.
Building a de novo hospice agency means obtaining Medicare certification, state licensure, and operational infrastructure from the ground up. In states without Certificate of Need (CON) requirements, the barriers are lower, but the timeline to a meaningful census and positive EBITDA is still 18–36 months in most markets. Success depends heavily on having pre-existing referral relationships, strong clinical leadership, and sufficient capital to fund operating losses during the ramp-up period. De novo development is a viable strategy for operators with a specific geographic opportunity or a clinical network that competitors cannot easily replicate.
Operators with deep pre-existing referral networks in a specific underserved geography, clinical entrepreneurs with a defined market gap and sufficient capital reserves to fund an 18–30 month ramp, or existing home health agencies seeking to add hospice services in a non-CON state.
For most lower middle market buyers in hospice and palliative care, acquisition is the clearly superior path. The combination of Medicare certification barriers, referral relationship dependency, clinical staffing competition, and the relationship-driven nature of hospice admissions makes de novo development a high-risk, slow-return strategy for all but the most operationally experienced clinical entrepreneurs with specific market advantages. A well-underwritten acquisition at 4x–7x EBITDA of a Medicare-certified agency with a clean compliance record, diversified referral network, and stable clinical team delivers immediate cash flow, regulatory standing, and a platform for geographic expansion that would take 3–5 years and $500K–$1M+ in losses to replicate organically. De novo development makes strategic sense only in non-CON states with demonstrated referral gaps, where the operator has confirmed physician or SNF relationships ready to generate admissions from day one. Even then, the 18–36 month ramp and capital intensity should be stress-tested against the cost of simply acquiring a smaller agency in the same market.
Do you have an existing referral network — hospital discharge teams, palliative care physicians, or SNF relationships — that would generate hospice admissions within 60–90 days of opening, or would you be building those relationships from zero?
Is your target geography a CON state? If yes, how long and costly is the Certificate of Need process, and does a de novo path remain economically viable compared to acquiring an existing licensed agency?
Can you absorb 18–30 months of operating losses totaling $300K–$800K to fund a de novo ramp-up, or does your capital structure and investor timeline require cash-flowing assets from close?
Have you identified a specific acquisition target with a clean Medicare compliance record, stable ADC, and manageable cap exposure — and can you validate those metrics through rigorous due diligence including a Quality of Earnings and Medicare cost report review?
Is your strategic goal a single-market owner-operator model or a multi-market hospice platform? If platform scale is the objective, acquisition-led growth compresses your timeline by years and avoids the referral development risk that makes de novo expansion so capital-intensive in new geographies.
Browse Hospice & Palliative Care Businesses For Sale
Skip the build phase — acquire existing customers, revenue, and cash flow from day one.
Obtaining initial Medicare certification for a de novo hospice agency typically takes 6–18 months from entity formation. The process requires state licensure, a CMS Conditions of Participation survey, and federal enrollment through the Medicare Administrative Contractor. Delays are common due to survey backlog and documentation deficiencies. By contrast, acquiring an existing agency and processing a Change of Ownership (CHOW) typically takes 60–120 days, making acquisition dramatically faster for operators who need to generate revenue quickly.
Medicare-certified hospice agencies in the $1M–$5M revenue range typically trade at 4x–7x EBITDA, depending on ADC size and trajectory, compliance record, referral diversification, and geographic market. Agencies with growing census, clean survey history, ACHC or CHAP accreditation, and no Medicare cap exposure command premiums at the higher end of that range. Agencies with compliance concerns, referral concentration, or cap proximity trade at discounts. Strategic acquirers and PE-backed roll-up platforms may pay above this range for agencies that offer immediate geographic expansion value.
The Medicare hospice cap limits aggregate Medicare reimbursement per patient for a given agency in each cap year. If an agency's Medicare billings exceed the cap threshold — calculated based on the number of patients and a per-beneficiary cap amount updated annually by CMS — it must repay the excess to Medicare. In an acquisition, undisclosed cap exposure can represent a significant post-close liability. Buyers should always request the target's Medicare cost reports and cap calculations for the prior three years and project forward cap exposure as part of due diligence.
Yes, SBA 7(a) loans are a common financing vehicle for owner-operator buyers acquiring hospice agencies in the lower middle market. The hospice industry's strong cash flow characteristics, Medicare reimbursement stability, and tangible business value make it generally SBA-eligible. Loan amounts up to $5M are available, typically with 10-year terms for business acquisitions. However, SBA lenders will scrutinize Medicare compliance history, reimbursement concentration, and the seller's financial documentation closely. Buyers should engage an SBA lender with healthcare lending experience early in the process.
A Medicare Change of Ownership (CHOW) is the CMS process by which a hospice agency's Medicare provider agreement is transferred to a new owner. In an asset purchase, the buyer typically assumes the existing provider agreement through CHOW rather than applying for new certification, which is faster. The CHOW requires notification to CMS and the state survey agency, and the new owner assumes full responsibility for all existing and prior Medicare liabilities — including any undisclosed overpayments or compliance issues. This is why escrow holdbacks and representations and warranties insurance are common in hospice deals.
Hospice referral relationships are built on clinical trust, personal relationships, and demonstrated outcomes — not contracts or marketing spend. Hospital discharge planners, palliative care physicians, and SNF social workers refer patients to hospice agencies they know personally and trust to deliver compassionate, compliant care to their most vulnerable patients. Building these relationships from zero typically requires 12–24 months of consistent community presence, joint care coordination, and family satisfaction outcomes before referral volume becomes predictable. An acquired agency with an existing referral network short-circuits this process entirely, which is one of the most underappreciated value drivers in hospice M&A.
More Hospice & Palliative Care Guides
Get access to acquisition targets with real revenue, real customers, and real cash flow.
Create your free accountNo credit card required
For Buyers
For Sellers